Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function

• Published in: Medicinskij sovet no. 19; pp. 28 - 30
• Main Authors: S. F. Menshikova, M. A. Frolova, E. V. Glazkova, M. B. Stenina
• Format: Journal Article
• Language: English; Russian
• Published: Remedium Group LLC 11-11-2018
• Subjects: cyclin-dependent kinase inhibitors; hormone therapy; metastatic hormone-dependent breast cancer; ribociclib
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2018-19-28-30

Treatment of choice of metastatic hormone-dependent breast cancer regardless of age is hormone therapy (HT) even with visceral metastases. Now we have a new class of drugs called inhibitors of cyclin-dependent kinases 4/6, which significantly increase effectiveness of HT and prevent development of resistance to HT. In MONALEESA-7 inhibitor of cyclin-dependent kinases 4/6 ribociclib was studied in combination with ovarian suppression and hormone therapy in young patients with preserved ovarian function, and found no differences in the efficacy and safety of these drugs compared with menopausal patients. Our clinical experience strongly demonstrates the safety and efficacy of ribociclib in combination with HT and ovarian suppression in premenopausal patient with visceral metastases.